Predicting heart injury after non-cardiac surgery in urologic cancer patients
Official title: Prediction of Myocardial Injury After Major Non-Cardiac Surgery in Patients With Urologic Cancer: A Prospective Multicenter Observational Study
Run by Korea University Anam Hospital · NCT07634666 · Data updated 2026-11-12
Doctors are testing whether AI analysis of a preoperative ECG can identify which urologic cancer patients are at higher risk of heart injury or major heart problems after non-cardiac surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Korea University Anam Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | July 15, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | July 22, 2026 |
| Trial ID | NCT07634666 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 60 or older undergoing major non-cardiac surgery for urologic cancer who have a preoperative ECG and are at intermediate or higher surgical risk.
✕Probably not a fit
Patients without a high predicted risk or those lacking suitable data may not derive a clear benefit from the predictive approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, prospective observational study that looks at whether artificial intelligence applied to preoperative 12-lead ECGs can predict myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days post-surgery in patients with urologic cancer. Data on patient characteristics, perioperative factors, ECGs, labs, and outcomes will be collected to build and validate predictive signals. No intervention is being tested; the study focuses on risk stratification to guide perioperative care. The target population is adults aged 60 and older undergoing major non-cardiac surgery for urologic cancer with at least 30-day follow-up. Findings could help improve preoperative risk assessment and postoperative management by highlighting patients at higher risk for cardiovascular complications.
Why it matters
Potential benefit: If successful, the test could improve preoperative risk stratification and guide perioperative management to reduce heart-related complications.
How similar studies have gone: Previous work in perioperative risk prediction has shown promise with ECG-based and AI approaches, but this specific application in urologic cancer patients undergoing major non-cardiac surgery is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 60 years * Patients scheduled for major non-cardiac surgery under general anesthesia due to urologic cancer (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy) * Patients who undergo preoperative standard 12-lead electrocardiography * Patients classified as having intermediate or higher surgical risk * Patients who can be followed for at least 30 days postoperatively * Patients who voluntarily provide written informed consent to participate in this study Exclusion Criteria: * History of major adverse cardiovascular events (MACE) within 6 months prior to surgery * Inability to obtain essential clinical information required for study participation and follow-up * Patients who are not hospitalized after surgery * Individuals deemed inappropriate for participation in the study by the investigator due to legal or psychiatric reasons
Where it's running
-
Seoul St. Mary's Hospital, The Catholic University of Korea
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Dong Hyuck Cho, MD, PhD — Korea University Anam Hospital
- Study coordinator: Dong Hyuck Cho, MD, PhD
- Email: why012@gmail.com
- Phone: +82-2-920-5448
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood extracellular vesicles to detect chemotherapy-related nerve damage.
We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.
-
Web app for reporting side effects during radiation therapy
This project will try a web app that lets people receiving radiation for breast, gynecologic, or urologic cancers report symptoms and quality of life so clinicians can spot problems earlier.
-
Vaginal Dilator Therapy After Pelvic Radiation
This study tests a new behavioral program to help women who had pelvic radiation use vaginal dilators more regularly.
-
Landiolol to prevent fast heart rates during major non-cardiac surgery in patients with cardiovascular risk
This will test whether giving the ultra‑short acting beta‑blocker landiolol to people over 45 with cardiovascular risk factors who are having major non‑cardiac surgery can keep heart rate below 90 bpm throughout the perioperative period and reduce heart injury.
-
Using CCTA to Manage Non-Obstructive Coronary Artery Disease
This study is testing if using a special heart scan called CCTA to manage non-obstructive coronary artery disease can help people control their cholesterol better and lower their risk of serious heart problems compared to regular care.
-
Exploring the link between imaging and tumor environment in urologic cancer
This study looks at how CT and MRI scans relate to the tumor environment and outcomes in patients with urologic cancer to see if imaging can help predict their prognosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.